Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Human Irisin Concentration in Sarcopenia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
K. M. Choi, Korea University
ClinicalTrials.gov Identifier:
NCT01874912
First received: June 3, 2013
Last updated: June 7, 2013
Last verified: June 2013
  Purpose

Irisin has been identified as a novel myokine that drives brown-fat-like conversion of white adipose tissue. In this cross-sectional study, the researches investigated whether serum irisin levels are decreased in patients with sarcopenia compared with control subjects with normal muscle mass, and assessed the association between serum irisin levels and various metabolic parameters.


Condition
Sarcopenia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional

Further study details as provided by Korea University:

Primary Outcome Measures:
  • Serum concentration of irisin in the subjects with sarcopenia [ Time Frame: 12 week ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The relationship of serum irisin levels with lipid profiles [ Time Frame: 12 week ] [ Designated as safety issue: No ]
  • The relationship of serum irisin levels with skeletal muscle mass index [ Time Frame: 12 wks ] [ Designated as safety issue: No ]

Enrollment: 406
Study Start Date: November 2009
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Patients in Korean Sarcopenic Obesity Study (KSOS), an prospective observational cohort study designed to examine the prevalence of sarcopenia and sarcopenic obesity in Korean adults and to evaluate their effects on metabolic disorders and health outcomes.

Criteria

Inclusion Criteria:

  • 20<age<80
  • apparently healthy subjects

Exclusion Criteria:

  • a history of cardiovascular disease
  • diabetes
  • stage 2 hypertension
  • malignancy
  • severe renal or hepatic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01874912

Locations
Korea, Republic of
Korea University Guro Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Korea University
  More Information

No publications provided by Korea University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: K. M. Choi, Professor, Korea University
ClinicalTrials.gov Identifier: NCT01874912     History of Changes
Other Study ID Numbers: SO(IRISIN)
Study First Received: June 3, 2013
Last Updated: June 7, 2013
Health Authority: South Korea: Institutional Review Board

Additional relevant MeSH terms:
Sarcopenia
Atrophy
Muscular Atrophy
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Manifestations
Pathological Conditions, Anatomical
Signs and Symptoms

ClinicalTrials.gov processed this record on November 27, 2014